Search

Displaying results 1201 - 1210 of 2674 in total
  1. Target

    Transient receptor potential cation channel subfamily V member 4

    go.drugbank.com/bio_entities/BE0009159
    TargetHumans

    Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity (PubMed:16293632, PubMed:18695040, PubMed:18826956, PubMed:22526352, PubMed:23136043, PubMed:29899501). Activation by exposure to hypoto...

    Polypeptides: Transient receptor potential cation channel subfamily V member 4Synonyms: Vanilloid receptor-like channel 2, Vanilloid receptor-like protein 2
  2. Target

    B-cell antigen receptor complex-associated protein beta chain

    go.drugbank.com/bio_entities/BE0009680
    TargetHumans

    Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to

    Polypeptides: B-cell antigen receptor complex-associated protein beta chain
  3. Target

    Transient receptor potential cation channel subfamily M member 4

    go.drugbank.com/bio_entities/BE0009748
    TargetHumans

    Calcium-activated selective cation channel that mediates membrane depolarization (PubMed:12015988, PubMed:12842017, PubMed:29211723, PubMed:30528822). While it is activated by increase in intracellular Ca(2+), it is impermeable to it (Pu...

    Polypeptides: Transient receptor potential cation channel subfamily M member 4Synonyms: Long transient receptor potential channel 4
  4. Drug

    Miricorilant

    go.drugbank.com/drugs/DB16234
    Investigational

    Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent

  5. Drug

    Ergoloid mesylate

    go.drugbank.com/drugs/DB01049
    Approved

    [L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. … [A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued.

    Categories: Ergot-derivative Dopamine Receptor Agonists
  6. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. It is a taurine conjugate of ursodeoxycholic acid with comparable therapeutic effi...

  7. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 respectively.[L34793,L49535]

  8. Drug

    Gadobenic acid

    go.drugbank.com/drugs/DB00743
    ApprovedInvestigational

    [A1139] Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance.[A263166]

  9. Drug

    Levetiracetam

    go.drugbank.com/drugs/DB01202
    ApprovedInvestigational

    Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically un...

    Products: KEPPRA 750MG FTA, Nra-levetiracetam
  10. Drug

    Celivarone

    go.drugbank.com/drugs/DB16012
    Investigational

    Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 Mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent